India Pharma Outlook Team | Tuesday, 02 December 2025
Eli Lilly is rolling out a major Zepbound price cut, lowering the cost of its single-dose vials to make the obesity drug easier for patients to afford.
The updated pricing is now live through LillyDirect, the company's digital health platform, marking another push to shrink out-of-pocket expenses in a market where treatment costs remain a major barrier.
The move lands just weeks after Lilly said it would slash prices on its Zepbound multi-dose pens once the FDA signs off. By cutting vial prices now, the drugmaker is broadening access across all delivery formats and keeping pressure on competitors in the fast-growing obesity drug space.
Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future
With a prescription, patients can get the 2.5 mg starter dose for $299 per month, the 5 mg dose for $399, and all other approved strengths for $449 through the Zepbound Self Pay Journey Program.
“Far too many people who need obesity treatments still face cost and coverage barriers,” said Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities. “Today’s action underscores Lilly’s commitment to improving access across the obesity care landscape. We will keep working to provide more options - expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need.”
Zepbound is a weekly injectable that helps adults with obesity—or adults who are overweight with related medical issues—lose and maintain weight. It may also improve moderate-to-severe obstructive sleep apnea in adults with obesity. The drug, which contains tirzepatide, comes in six single-dose pen strengths. The Zepbound maintenance doses range from 5 mg to 15 mg, depending on the treatment goal.
